Although glucocorticoids are central to the treatment of idiopathic inflammatory myopathies, these drugs, paradoxically, have catabolic effects on skeletal muscle. Mechanisms that govern the beneficial and adverse effects of these agents are increasingly understood; as the authors explain, glucocorticoid therapy will be optimized as a result, but new targets that will lead to much-needed alternative therapeutic options are also expected to emerge.
- Beatriz Y. Hanaoka
- Charlotte A. Peterson
- Leslie J. Crofford
